Welcome to our podcast!
Listen as Natascha Eckert, head of university relations at Siemens, on the elements of mature university-industry partnerships, Siemens’ philosophy of managing those relationships, and taking action to promote women in tech leadership–not just talking about it.
In any partnership, it’s absolutely crucial that you create from the beginning a mutual understanding and really follow on with open and transparent communication.
Malcolm Skingle, GlaxoSmithKline’s director, academic liaison, discusses the critical role of industry- academic collaboration to address the world’s big scientific challenges and what it takes for industry-academic collaborations to succeed.
If you have a diverse set of collaborators, it allows you to tap into different ways of thinking, different skill sets, and this absolutely accelerates the innovation process. I’ve seen it on many, many occasions.
Chris Austin, director of the National Institutes of Health’s National Center for Advancing Translational Sciences, on the power of collaboration for translating basic science into the cures and therapies that benefit society.
If you’re really going to be innovative, you have to think about no only innovation of the science, but the innovation of your partners and the way you think about collaboration itself.
David Reed, associate provost and director of research and collections for the Florida museum of natural history at the university of Florida, describes how the university will leverage a $50 million hardware gift from industry partner NVIDIA to expand AI research and development across university programs and extend workforce development training in AI across the state.
The $50 million hardware gift is incredible and game changing for the University of Florida, but the partnership is much deeper than that. It focuses on not just the research, but teaching, outreach, and workforce development.
Daron Green, Facebook’s director of research operations and academic relations, on talent development, industry-based faculty employment, and how partnerships with university-based research broaden technology exploration and the scope of industry innovation.
We need academia to still be innovating. We need people challenging the approaches that otherwise might stagnate within companies.
In this wide-ranging discussion, Matt Ridley—author, journalist, businessman—dives into the role of serendipity and collaboration in innovation, why innovation itself is an “infinite improbability,” and how freedom is the necessary element for innovation to flourish.
Nobody does innovation from first principles, all on his own in an ivory tower, and achieves a good result. What happens is that people go out there and make mistakes and eventually get it right. You can tell the stories of the Wright brothers or Jeff Bezos and Amazon as a string of failures. They made disastrous mistakes at every step. And yet they learned from those mistakes.
John Bamforth, director, Eshelman Institute for Innovation, University of North Carolina, Chapel Hill, on what it takes to bring the world’s top pharmaceutical researchers and industry leaders in an open-science partnership to ensure we’re ready for the next pandemic, the Rapidly Emerging Antiviral Drug Discovery Initiative (READDI).
No one would have wished, of course, for COVID-19 to have become what it is. But in another sense, it really has galvanized people to think in a more collaborative way in order to get these global problems solved.
Cynthia Sweet, the University of Pittsburgh’s associate vice chancellor for economic partnerships, on partnership intentionality, building internal and external relationships, and leading through influence rather than authority.
There are so many people working towards partnerships, and we don’t control all of those activities or the actions of others. And so you really have to rely on the relationships you build internally and externally. You lead through influence rather than authority.
Doug Maughan, office head for NSF’s Convergence Accelerator Program, on flexibility, new topics of research interest, and what happens in that niche between basic research and commercialization.
We’ve seen a whole range of partners—large multinationals, all the way down to small startups. And what is really quite interesting is that all of them can participate and play a role. And that’s not a normal environment.